Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement
- PMID: 36007560
- DOI: 10.1016/j.xphs.2022.08.023
Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement
Abstract
Co-amorphization is a promising approach to stabilize drugs in the amorphous form. Olanzapine, a poorly water-soluble drug was used in this study. Sulfonic acids (saccharin, cyclamic acid and acesulfame), free and in salt forms, were used as co-formers and compared with carboxylic acids commonly used in the preparation of co-amorphous systems. Several manufacturing techniques were tested, and the co-amorphous systems characterized by differential scanning calorimetry, X-ray powder diffraction, thermogravimetry and Fourier-transform infrared spectroscopy. Free sulfonic acids produced co-amorphous systems with the drug, unlike their salts. Spectroscopy data suggests the formation of salts between olanzapine and the sulfonic acids, used as co-formers. The co-amorphous system produced with saccharin by solvent evaporation, showed the most notable solubility enhancement (145 times). The stability of amorphous and co-amorphous olanzapine systems was assessed upon exposure to stress conditions during storage. Amorphized olanzapine readily reconverted back to the crystalline form while sulfonic acids:olanzapine co-amorphous were stable for up to 24 weeks in low/medium humidity conditions (11-75% RH). Results highlight the potential advantages offered by sulfonic acids as co-formers to produce stable and more soluble co-amorphous olanzapine.
Keywords: Carboxylic acids; Co-amorphous systems; Olanzapine; Solubility; Stability; Sulfonic acid derivatives.
Copyright © 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
Similar articles
-
Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.Int J Mol Sci. 2022 Sep 6;23(18):10234. doi: 10.3390/ijms231810234. Int J Mol Sci. 2022. PMID: 36142179 Free PMC article.
-
In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.Pharmaceutics. 2022 Nov 24;14(12):2587. doi: 10.3390/pharmaceutics14122587. Pharmaceutics. 2022. PMID: 36559080 Free PMC article.
-
Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.Int J Mol Sci. 2023 Mar 14;24(6):5533. doi: 10.3390/ijms24065533. Int J Mol Sci. 2023. PMID: 36982605 Free PMC article.
-
[The development of co-amorphous drug systems].Yao Xue Xue Bao. 2013 May;48(5):648-54. Yao Xue Xue Bao. 2013. PMID: 23888685 Review. Chinese.
-
Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs.Drug Discov Today. 2024 Feb;29(2):103883. doi: 10.1016/j.drudis.2024.103883. Epub 2024 Jan 14. Drug Discov Today. 2024. PMID: 38219970 Review.
Cited by
-
Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.Int J Mol Sci. 2022 Sep 6;23(18):10234. doi: 10.3390/ijms231810234. Int J Mol Sci. 2022. PMID: 36142179 Free PMC article.
-
In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.Pharmaceutics. 2022 Nov 24;14(12):2587. doi: 10.3390/pharmaceutics14122587. Pharmaceutics. 2022. PMID: 36559080 Free PMC article.
-
Cutting-Edge Approaches in the Co-Amorphization Process.Pharmaceutics. 2025 Jun 29;17(7):850. doi: 10.3390/pharmaceutics17070850. Pharmaceutics. 2025. PMID: 40733059 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources